Bausch Health (BLCO) - Koefisien utang jangka dawa marang modal

Bausch + Lomb Corporation (BLCO) is expanding its ophthalmology footprint by acquiring lens and eye drop developers and implementing new surgical techniques through partnerships with medical centers. This price action, where the indicator stands at 0.79, correlates with Brent Saunders' course on asset restructuring. Stringent testing requirements and brand authority create significant barriers to entry for new market players.

This ratio measures the proportion of long-term liabilities within the equity structure, allowing investors to assess the stability of financial leverage and the risks of debt dependency. By analyzing the long-term debt-to-equity ratio, one can determine how effectively Bausch + Lomb Corporation (BLCO) finances the development of global logistics and the cold chain while maintaining the profitability of ophthalmic drug distribution.